Vitiligo Repigmentation with Melanoma Progression During Pembrolizumab Treatment.
Vitiligo Repigmentation with Melanoma Progression During Pembrolizumab Treatment. Acta Derm Venereol. 2019 Apr 16;: Authors: Nardin C, Pelletier F, Puzenat E, Aubin F PMID: 31017249 [PubMed - as supplied by publisher]
All gray horses inherited a single gene mutation, STX17G, that unbalances melanocyte behavior to cause graying and propensities to develop vitiligo and melanoma. The coat color genes ASIPa and MC1RE add risk such that relative likelihood of melanoma based on pregraying coat color is black > bay > chestnut. Melanomas begin at about 4 years. Locoregional control of melanoma masses depends on surgical removal and/or intralesional chemotherapy (possibly with adjunctive hyperthermia or electroporation). Systemic treatment is not evidence based but immunomodulators (cimetidine, levamisole) and vaccines can be tried.
CONCLUSIONS: Unlike in Caucasians, the risk of skin cancer was increased in the Korean vitiligo population. Nonetheless, it is noteworthy that the skin cancer incidence in Korean vitiligo patients was lower than that of their Caucasian counterparts. Due to possible ethnic differences in the susceptibility to skin cancer, skin cancer surveillance in the vitiligo population may be adjusted to race. This article is protected by copyright. All rights reserved. PMID: 31233609 [PubMed - as supplied by publisher]
This article is protected by copyright. All rights reserved. PMID: 31063266 [PubMed - as supplied by publisher]
Hui Zhou, Xiaoyan Fu, Qian Li and Ting Niu* Department of Hematology and Research Laboratory of Hematology, West China Hospital, Sichuan University, Chengdu, China Background: Immune checkpoint inhibition therapy with monoclonal antibody against programmed cell death protein 1 (PD-1), including nivolumab and pembrolizumab, has demonstrated powerful clinical efficacy in the treatment of advanced cancers. However, there is no evidence-based systematic review on the safety and efficacy of anti-PD-1 antibody in treating lymphoma. Methods: To evaluate the safety and efficacy of nivolumab/pembrolizumab, we analyzed clin...
AbstractForming the outer body barrier, our skin is permanently exposed to pathogens and environmental hazards. Therefore, skin diseases are among the most common disorders. In many of them, the immune system plays a crucial pathogenetic role. For didactic and therapeutic reasons, classification of such immune-mediated skin diseases according to the underlying dominant immune mechanism rather than to their clinical manifestation appears to be reasonable. Immune-mediated skin diseases may be mediated mainly by T cells, by the humoral immune system, or by uncontrolled unspecific inflammation. According to the involved T cell...
Roser Calvo* Patient Safety, Safety Science, AstraZeneca Pharmaceuticals, Gaithersburg, MD, United States Immune-related hematological adverse events are amongst the rare but potentially life-threatening complications of immune checkpoint inhibitors. The spectrum of these toxicities is broadening as the number of patients exposed to these agents is increasing. Yet, they are still relatively unknown to many clinicians, possibly due to a lack of specific diagnostic criteria, which poses a challenge for their recognition and proper reporting, and partly due to their low incidence, often too low to be noted in most c...
In conclusion, the spectrum of autoimmune reactions induced by immune-checkpoint inhibitors should be restricted in the near future to only these specific favorable autoimmune mechanisms. In this way, the unnecessary autoimmune reactions/autoaggressions could be avoided (a better quality of life), and treatment specificity and efficiency should increase (a higher response rate for melanoma therapy).
In conclusion, this case report suggests that a major regression of multiple nevi on ipilimumab might be associated with immunotherapy response.
This study aims to investigate whether folic acid could protect human melanocyte against oxidative damage and to elucidate the underlying pharmacological mechanism. And we demonstrate that folic acid could protect melanocytes form oxidative damage. Folic acid is of great therapeutic potential in the treatment of vitiligo. Vitiligo is a common skin disease characterized by the loss of functional melanocytes. Previous studies have indicated that oxidative stress plays a pivotal role in the onset of vitiligo.
Inducible HSP70 (HSP70i) is implicated in the development of autoimmune vitiligo and is overexpressed in melanoma. We generated an expression construct encoding a single amino acid modification to the dendritic cell (DC) activating moiety (HSP70iQ435A). A topical application of the DNA construct has now demonstrated efficacy in reversing autoimmunity in Sinclair swine without obstructing anti-melanoma responses. We postulate that treatment with the HSP70iQ435A construct elicits a humoral response to stress protein selectively expressed on the surface of melanoma cells, providing measurable anti-tumor protection.